Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1996 Sep;122(9):559–565. doi: 10.1007/BF01213553

Alterations of thep53, Rb andMDM2 genes in osteosarcoms

Carl W Miller 1,✉, Abdulkarim Aslo 1, Alvina Won 1, Michael Tan 1, Beatrice Lampkin 2, H Phillip Koefflar 1
PMCID: PMC12200418  PMID: 8781571

Abstract

Molecular defects affecting tumor-suppressor genes are an important step in the genesis of sarcomas. For example, inheritance of a defectiveRb orp53 gene predisposes the carrier to develop osteosarcoma, among other malignancies. In this study, we have assessed the occurrence ofp53, Rb andMDM2 alterations in the same samples of osteosarcomas, along with representative samples of various other sarcomas. Point mutations of thep53 gene were found in 13 of 42 osteosarcomas and 1 of 8 leiomyosarcomas, and gross rearrangement of thep53 gene was demonstrated in 5 of 37 osteosarcomas. The retinoblastoma susceptibility gene (Rb) was either rearranged or deleted in 7 of 37 osteosarcomas, 1 of 7 soft-tissue sarcomas and 1 of 4 Ewing sarcomas. Remarkably, 5 of the osteosarcomas havingRb alterations also hadp53 mutations. Amplification and overexpression of theMDM2 oncogene may lead to increasedMDM2-p53 binding resulting in inactivation ofp53 function. A two- to threefold increase in the copy number ofMDM2 was detected in 7 of 37 samples, 5 of which were osteosarcomas. Amplification of theMDM2 gene occurred independently ofp53 mutation; one sample having threefold amplification ofMDM2 also had ap53 mutation. In summary, 34 alterations of thep53, Rb andMDM2 genes were found in 26 of 42 (62%) osteosarcomas.

Key words: p53, Rb, MDMZ, Osteosarcoma, Sarcoma

References

  1. Abramson DH, Ronner HJ, Ellsworth RM (1979) Second tumors in nonirradiated bilateral retinoblastoma. Am J Ophthalmol 87: 624–637 [DOI] [PubMed] [Google Scholar]
  2. Andreassen A, Oyjord T, Hovig E, Holm R, Florenes VA, Nesland JM, Myklebost O, Hoie J, Bruland OS, Borresen AL, Fodstadt O (1993)p53 abnormalities in different subtypes of human sarcomas. Cancer Res 53:468–471 [PubMed] [Google Scholar]
  3. Araki N, Uchida A, Kimura T, Yoshikawa H, Aoki Y, Ueda T, Takai S, Miki T, Ono K (1991) Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. Clin Orthop 270:271–277 [PubMed] [Google Scholar]
  4. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, O'Malley BW (1988) Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 85:3294–3298 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brachman DG, Hallahan DE, Beckett MA, Yandell DW, Weichselbaum RR (1991)p53 gene mutations and abnormal retinoblastoma protein in radiation-induced human sarcomas. Cancer Res 51:6393–6396 [PubMed] [Google Scholar]
  6. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP (1988) A variation in the structure of the protein-coding region of the humanp53 gene. Gene 70:245–252 [DOI] [PubMed] [Google Scholar]
  7. Carbone D, Chiba I, Mitsudomi T (1991) Polymorphism at codon 213 within thep53 gene. Oncogene 6:91–92 [PubMed] [Google Scholar]
  8. Cheng J, Haas M (1990) Frequent mutations in thep53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502–5509 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fakharzadeh S, Trusko RS, George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565–1569 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Feinberg AP, and Vogelstein B (1983) A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6–13 [DOI] [PubMed] [Google Scholar]
  11. Forus A, Florenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O (1993) Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not includeMDM2. Cell Growth Differ 4:1065–1070 [PubMed] [Google Scholar]
  12. Fuchs N, Winkler K (1993) Osteosarcoma. Curr Opin Oncol 5:667–671 [DOI] [PubMed] [Google Scholar]
  13. Fung YK, Murphree AL, T'Ang A, Qian J, Hinrichs SH, Benedict WF (1987) Structural evidence for the authenticity of the human retinoblastoma gene. Science 236:1657–1661 [DOI] [PubMed] [Google Scholar]
  14. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643–646 [DOI] [PubMed] [Google Scholar]
  15. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in thep53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878 [PubMed] [Google Scholar]
  16. Harlow E, Williamson NM, Ralston R, Helfman DM, Adams TE (1985) Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol Cell Biol 5:1601–1610 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821–1828 [DOI] [PubMed] [Google Scholar]
  18. Iavarone A, Matthay K, Steinkirchner TM, Israel MA (1992) Germline and somaticp53 gene mutations in multifocal osteogenic sarcoma. Proc Natl Acad Sci USA 89:4207–4209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT (1993) Coamplification of theCDK4 gene withMDM2 andGLI in human sarcomas. Cancer Res 53:5535–5541 [PubMed] [Google Scholar]
  20. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH (1993)MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53:16–18 [PubMed] [Google Scholar]
  21. Laimins LA (1993) The biology of human papillomaviruses: from warts to cancer. Infect Agents Dis 2:74–86 [PubMed] [Google Scholar]
  22. Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261–263 [DOI] [PubMed] [Google Scholar]
  23. Lee WH, Bookstein R, Lee EY (1988) Studies on the human retinoblastoma susceptibility gene. J Cell Biochem 38:213–227 [DOI] [PubMed] [Google Scholar]
  24. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923–935 [DOI] [PubMed] [Google Scholar]
  25. Lubbert M, Mirro J Jr, Miller CW, Kahan J, Isaac G, Kitchingman G, Mertelsmann R, Herrmann F, McCormick F, Koeffler HP (1990) N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood 75:1163–1169 [PubMed] [Google Scholar]
  26. Ludlow JW (1993) Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB J 7:866–871 [DOI] [PubMed] [Google Scholar]
  27. McCormick F, Harlow E (1980) Association of a murine 53,000-dalton phosphoprotein with simian virus 40 large-T antigen in transformed cells. J Virol 3:213–224 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990) Germ linep53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233–1238 [DOI] [PubMed] [Google Scholar]
  29. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ (1987) Rearrangement of thep53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84:7716–7719 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Merlo GR, Cropp CS, Callahan R, Takahashi T (1991) Detection of loss of heterozygosity in tumor DNA samples by PCR. Biotechniques 11:166–170 [PubMed] [Google Scholar]
  31. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler HP (1990) Frequency and structure ofp53 rearrangements in human osteosarcoma. Cancer Res 50:7950–7954 [PubMed] [Google Scholar]
  32. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) TheMDM-2 oncogene product forms a complex with thep53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245 [DOI] [PubMed] [Google Scholar]
  33. Moran E (1993) Interaction of adenoviral proteins with pRB and p53. FASEB J 7:880–885 [DOI] [PubMed] [Google Scholar]
  34. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK (1990) Mechanisms ofp53 loss in human sarcomas. Proc Natl Acad Sci USA 87:5863–5867 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in thep53 gene occur in diverse human tumour types. Nature 342:705–708 [DOI] [PubMed] [Google Scholar]
  36. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding ap53-associated protein in human sarcomas. Nature 358:80–83 [DOI] [PubMed] [Google Scholar]
  37. Oren M (1994) Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 5:221–227 [PubMed] [Google Scholar]
  38. Ozaki T, Ikeda S, Kawai A, Inoue H, Oda T (1993) Alterations of retinoblastoma susceptible gene accompanied by c-myc amplification in human bone and soft tissue tumors. Cell Mol Biol 39:235–242 [PubMed] [Google Scholar]
  39. Pedeutour F, Suijkerbuijk RF, Forus A, Van Gaal J, Van de Klundert W, Coindre JM, Nicolo G, Collin F, Van Haelst U, Huffermann K, Turc-Carel C (1994) Complex composition and coamplification ofSAS andMDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chromosomes Cancer 10:85–94 [DOI] [PubMed] [Google Scholar]
  40. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP (1994) Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54:4299–4303 [PubMed] [Google Scholar]
  41. Reissmann PT, Simon MA, Lee WH, Slamon DJ (1989) Studies of the retinoblastoma gene in human sarcomas. Oncogene 4:839–843 [PubMed] [Google Scholar]
  42. Romano JW, Ehrhart JC, Duthu A, Kim CM, Appella E, May P (1989) Identification and characterization of ap53 gene mutation in a human osteosarcoma cell line. Oncogene 4:1483–1488 [PubMed] [Google Scholar]
  43. Scheffer H, Kruize YC, Osinga J, Kuiken G, Oosterhuis JW, Leeuw JA, Schraffordt Koops H, Buys CH (1991) Complete association of loss of heterozygosity of chromosomes 13 and 17 in osteosarcoma. Cancer Genet Cytogenet 53:45–55 [DOI] [PubMed] [Google Scholar]
  44. Scholz RB, Kabisch H, Weber B, Roser K, Delling G, Winkler K (1992) Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol 9:125–137 [DOI] [PubMed] [Google Scholar]
  45. Shew JY, Ling N, Yang XM, Fodstad O, Lee WH (1989) Antibodies detecting abnormalities of the retinoblastoma susceptibility gene product (pp110RB) in osteosarcomas and synovial sarcomas. Oncogene Res 4:205–214 [PubMed] [Google Scholar]
  46. Smith-Sorensen B, Gebhardt MC, Kloen P, McIntyre J, Aguilar F, Cerutti P, Borresen AL (1993) Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum Mutat 2:274–285 [DOI] [PubMed] [Google Scholar]
  47. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B (1994) Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 57:1–9 [DOI] [PubMed] [Google Scholar]
  48. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747–749 [DOI] [PubMed] [Google Scholar]
  49. Stratton MR, Williams S, Fisher C, Ball A, Westbury G, Gusterson BA, Fletcher CD, Knight JC, Fung YK, Reeves BR, Cooper CS (1989) Structural alterations of the RB1 gene in human soft tissue tumours. Br J Cancer 60:202–205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher CD, Ball A, Thomas M, Gusterson BA, Cooper CS (1990) Mutation of thep53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 5:1297–1301 [PubMed] [Google Scholar]
  51. Toguchida J, Ishizaki K, Sasaki MS, Ikenaga M, Sugimoto M, Kotoura Y, Yamamuro T (1988) Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. Cancer Res 48:3939–3943 [PubMed] [Google Scholar]
  52. Toguchida J, Ishizaki K, Nakamura Y, Sasaki MS, Ikenaga M, Kato M, Sugimoto M, Kotoura Y, Yamamuro T (1989) Assignment of common allele loss in osteosarcoma to the subregion 17p13 Cancer Res 49:6247–6251 [PubMed] [Google Scholar]
  53. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB, Weichselbaum RR, Ishizaki K, Yandell DW (1992a) Mutation spectrum of thep53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194–6199 [PubMed] [Google Scholar]
  54. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera Geichselbaum RR, Yandell DW, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, et al (1992b) Prevalence and spectrum of germline mutations of thep53 gene among patients with sarcoma. N Engl J Med 326:1301–1308 [DOI] [PubMed] [Google Scholar]
  55. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, Yamamuro T (1994) Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54: 3042–3048 [PubMed] [Google Scholar]
  56. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323–330 [DOI] [PubMed] [Google Scholar]
  57. Xu HJ, Hu SX, Hashimoto T, Takahashi R, Benedict WF (1989) The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells. Oncogene 4:807–812 [PubMed] [Google Scholar]
  58. Yamaguchi T, Toguchida J, Yamamuro T, Kotoura Y, Takada N, Kawaguchi N, Kaneko Y, Nakamura Y, Sasaki MS, Ishizaki K (1992) Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res 52:2419–2423 [PubMed] [Google Scholar]
  59. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES